Spanish modified Story Memory Technique efficacious for Mexicans with multiple sclerosis

February 19, 2020

East Hanover, NJ. February 19, 2020. A team of researchers reported preliminary findings for efficacy of the Spanish version of the modified Story Memory Technique, a cognitive intervention developed at Kessler Foundation (KF-mSMT™). Their study, conducted in Mexicans with multiple sclerosis, is an important step toward addressing the void in evidence-based rehabilitative interventions for treating the cognitive effects of multiple sclerosis across diverse cultural populations. The article, "Efficacy of the Spanish modified Story Memory Technique in Mexicans with multiple sclerosis: A pilot randomized controlled trial," (doi: 10.3233/NRE-192808) was epublished on November 28, 2019 by NeuroRehabilitation.

The authors are Denise Krch, PhD, Anthony Lequerica, PhD, and Nancy Chiaravalloti, PhD, of Kessler Foundation, Adriana Aguayo Arelis, MSc, and Brenda V. Rabago Barajas, MS, of Universidad Enrique D´?az de Leon and the Mexican MS Foundation, Guadalajara, Mexico, and Juan Carlos Arango-Lasprilla, MD, of Cruces University Hospital, Bizkaia, Spain, Basque Foundation for Science, Bilbao, Spain, and University of the Basque Country, Leoia, Spain.

While problems with learning and memory occur across populations with multiple sclerosis around the world, the availability of evidence-based cognitive interventions in different languages is limited. The lack of interventions in Spanish presents a barrier to the rehabilitation of many individuals in the Hispanic community who have cognitive deficits caused by multiple sclerosis. An international team of researchers has adapted the English language KF-mSMT into Spanish, for use in the cognitive rehabilitation of Mexicans with multiple sclerosis.

In this pilot study, 20 participants with multiple sclerosis, relapsing-remitting type, were randomized to either treatment (n?=?10) or placebo control (n?=?10) groups. The treatment group received the Spanish adaptation of the KF-mSMT, a 10-session intervention that teaches imagery and context to facilitate learning. The control group participated in 10 sessions based on similar content and presentation. All participants underwent baseline and follow-up neuropsychological assessments. Individuals in the treatment group showed significant improvements in learning and life satisfaction relative to the control group, suggesting that that this adaptation of the KF-mSMT may be an effective rehabilitative tool in Spanish-speaking populations with MS, according to Dr. Krch, senior research scientist in the Center for Traumatic Brain Injury Research.

"This is an example of how cultural adaptation can be an effective way to extend evidence-based interventions to non-English speaking populations," said Dr. Krch. "The positive outcomes seen in this pilot study of urban-based Mexicans have important implications," she noted. "While further testing is needed, we anticipate that this adaptation of the modified Story Memory Technique will be applicable to the diverse Spanish-speaking population in the U.S., in addition to those with Mexican heritage."
Kessler Foundation researchers have documented the efficacy of this tool in the U.S. for English-speaking populations with traumatic brain injury as well as multiple sclerosis. "Based on our prior research," noted Dr. Krch, "the modified Story Memory Technique may also prove useful in the rehabilitation of Spanish-speakers with cognitive deficits caused by traumatic brain injury."

The KF-mSMT is available from Kessler Foundation in English and Spanish for use by rehabilitation professionals. Contact the Foundation by email at

Funding: National Institute on Disability Independent Living and Rehabilitation Research (H133G090078)

About MS Research at Kessler Foundation

Kessler Foundation's cognitive rehabilitation research in MS is funded by grants from the National Institutes of Health, the National Institute on Disability, Independent Living, and Rehabilitation Research, National MS Society, Consortium of Multiple Sclerosis Centers, the Patterson Trust, Biogen Idec, Hearst Foundations, the International Progressive MS Alliance, and Kessler Foundation. Under the leadership of John DeLuca, PhD, senior VP for Research & Training, and Nancy Chiaravalloti, PhD, director of the Centers for Neuropsychology, Neuroscience and Traumatic Brain Injury Research, scientists have made important contributions to the knowledge of cognitive decline in MS and developed new treatments. Collaborations with the Center for Mobility and Rehabilitation Engineering Research have resulted in new lines of research aimed at improved both cognitive and motor functions. Clinical studies span new learning, memory, executive function, attention and processing speed, emotional processing, employment, cognitive fatigue, mobility, and the interrelatedness of cognitive and physical deficits. Research tools include innovative applications of neuroimaging, mobile imaging technologies, robotics, eye-tracking, virtual reality, and other technologies. Neuroimaging studies are conducted at the research-dedicated Rocco Ortenzio Neuroimaging Center at Kessler Foundation. Kessler researchers and clinicians have faculty appointments in the department of Physical Medicine and Rehabilitation at Rutgers New Jersey Medical School.

About Kessler Foundation

Kessler Foundation, a major nonprofit organization in the field of disability, is a global leader in rehabilitation research that seeks to improve cognition, mobility and long-term outcomes, including employment, for people with neurological disabilities caused by diseases and injuries of the brain and spinal cord. Kessler Foundation leads the nation in funding innovative programs that expand opportunities for employment for people with disabilities. For more information, visit

Stay Connected

Twitter |
Facebook |
YouTube |
Instagram |
iTunes & SoundCloud |

For more information, or to interview an expert, Contact: Carolann Murphy, 973.324.8382,

Kessler Foundation

Related Multiple Sclerosis Articles from Brightsurf:

New therapy improves treatment for multiple sclerosis
A new therapy that binds a cytokine to a blood protein shows potential in treating multiple sclerosis, and may even prevent it.

'Reelin' in a new treatment for multiple sclerosis
In an animal model of multiple sclerosis (MS), decreasing the amount of a protein made in the liver significantly protected against development of the disease's characteristic symptoms and promoted recovery in symptomatic animals, UTSW scientists report.

Not all multiple sclerosis-like diseases are alike
Scientists say some myelin-damaging disorders have a distinctive pathology that groups them into a unique disease entity.

New therapeutic options for multiple sclerosis in sight
Strategies for treating multiple sclerosis have so far focused primarily on T and B cells.

Diet has an impact on the multiple sclerosis disease course
The short-chain fatty acid propionic acid influences the intestine-mediated immune regulation in people with multiple sclerosis (MS).

The gut may be involved in the development of multiple sclerosis
It is incompletely understood which factors in patients with multiple sclerosis act as a trigger for the immune system to attack the brain and spinal cord.

Slowing the progression of multiple sclerosis
Over 77,000 Canadians are living with multiple sclerosis, a disease whose causes still remain unknown.

7T MRI offers new insights into multiple sclerosis
Investigators from Brigham and Women's Hospital have completed a new study using 7 Tesla (7T) MRI -- a far more powerful imaging technology -- to further examine LME in MS patients

How to improve multiple sclerosis therapy
Medications currently used to treat multiple sclerosis (MS) can merely reduce relapses during the initial relapsing-remitting phase.

Vaccinations not a risk factor for multiple sclerosis
Data from over 12,000 multiple sclerosis (MS) patients formed the basis of a study by the Technical University of Munich (TUM) which investigated the population's vaccination behavior in relation to MS.

Read More: Multiple Sclerosis News and Multiple Sclerosis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to